What's new

Opinion/decision on a Paediatric investigation plan (PIP): Enspryng, satralizumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Nervous system disorders;Neurology, PIP number: P/0069/2024

Opinion/decision on a Paediatric investigation plan (PIP): Enspryng, satralizumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Nervous system disorders;Neurology, PIP number: P/0069/2024

Apr 25, 2025 - 13:43
 0
Opinion/decision on a Paediatric investigation plan (PIP): Enspryng, satralizumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Nervous system disorders;Neurology, PIP number: P/0069/2024
Opinion/decision on a Paediatric investigation plan (PIP): Enspryng, satralizumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Nervous system disorders;Neurology, PIP number: P/0069/2024
Read More

Tags:

Previous Article

Opinion/decision on a Paediatric investigation plan (PIP): Rydapt, Midostaurin, ...

Next Article

Procter and Gamble abaisse ses prévisions alors que les ventes se tassent

Related Posts

Development of a guideline on the quality aspects of mRNA vaccines - Scientific guideline

Development of a guideline on the quality aspects of mR...

Mar 31, 2025  0

Human medicines European public assessment report (EPAR): Gencebok, caffeine citrate, Date of authorisation: 19/08/2020, Revision: 8, Status: Authorised

Human medicines European public assessment report (EPAR...

Mar 12, 2025  0

Human medicines European public assessment report (EPAR): Neoclarityn, desloratadine, Date of authorisation: 15/01/2001, Revision: 48, Status: Authorised

Human medicines European public assessment report (EPAR...

Mar 5, 2025  0